Page 133 - 《中国药房》2022年20期
P. 133

of a potential interaction[J]. J Clin Psychopharmacol,  [22]  METHANEETHORN J,SRINGAM S. Factors influen-
              1996,16(1):68-71.                                   cing lithium pharmacokinetics in patients with acute ma‐
          [12]  MALHI G S,GESSLER D,OUTHRED T. The use of         nia:a population pharmacokinetic analysis[J]. Hum Psy‐
              lithium for the treatment of bipolar disorder:recommenda‐  chopharmacol,2019,34(3):e2697.
              tions from clinical practice guidelines[J]. J Affect Disord,  [23]  YAMAGUCHI D,TSUJI Y,SONODA M,et al. Popula‐
              2017,217:266-280.                                   tion pharmacokinetics and exposure-response of lithium
          [13]  汪作为,马燕桃,陈俊,等.中国双相障碍防治指南:基于                        carbonate in patients based on tubular reabsorption mecha‐
              循证的选择[J].中华精神科杂志,2017,50(2):96-100.                 nisms[J]. Eur J Drug Metab Pharmacokinet,2019,44(3):
          [14]  NOLEN W A,LICHT R W,YOUNG A H,et al. What is      329-338.
              the optimal serum level for lithium in the maintenance  [24]  FINDLING R L,LANDERSDORFER C B,KAFANTARIS
              treatment of bipolar disorder? A systematic review and  V,et al. First-dose pharmacokinetics of lithium carbonate
              recommendations from the ISBD/IGSLI Task Force on   in children and adolescents[J]. J Clin Psychopharmacol,
              treatment with lithium[J]. Bipolar Disord,2019,21(5):  2010,30(4):404-410.
              394-409.                                       [25]  LANDERSDORFER C B,FINDLING R L,FRAZIER
          [15]  SAJATOVIC M,STREJILEVICH S A,GILDENGERS A         J A,et al.Lithium in paediatric patients with bipolar dis-
              G,et al. A report on older-age bipolar disorder from the In‐  order:implications for selection of dosage regimens via‐
              ternational Society for Bipolar Disorders Task Force[J].Bi‐  population pharmacokinetics/pharmacodynamics[J]. Clin
              polar Disord,2015,17(7):689-704.                    Pharmacokinet,2017,56(1):77-90.
          [16]  SHULMAN K I,ALMEIDA O P,HERRMANN N,et al.    [26]  HOU L,HEILBRONNER U,DEGENHARDT F,et al.
              Delphi survey of maintenance lithium treatment in older  Genetic variants associated with response to lithium treat‐
              adults with bipolar disorder:an ISBD task force report[J].  ment in bipolar disorder:a genome-wide association study
              Bipolar Disord,2019,21(2):117-123.                  [J]. The Lancet,2016,387(10023):1085-1093.
          [17]  YOUNG R C,MULSANT B H,SAJATOVIC M,et al.     [27]  AMARE T A,SCHUBERT K O,HOU L,et al. Associa‐
              GERI-BD:a randomized double-blind controlled trial of  tion of polygenic score for schizophrenia and HLA anti‐
              lithium and divalproex in the treatment of mania in older  gen and inflammation genes with response to lithium in bi‐
              patients with bipolar disorder[J]. Focus(Am Psychiatr  polar affective disorder:a genome-wide association study
              Publ),2019,17(3):314-321.                           [J]. JAMA Psychiatry,2018,75(1):65-74.
          [18]  GAUTAM S,JAIN A,GAUTAM M,et al. Clinical prac‐  [28]  SZCZEPANKIEWICZ A,NAROZNA B,RYBAKOWSKI
              tice guidelines for bipolar affective disorder(BPAD)in  J K,et al. Genes involved in stress response influence
              children and adolescents[J]. Indian J Psychiatry,2019,61  lithium efficacy in bipolar patients[J]. Bipolar Disord,
              (Suppl 2):294-305.                                  2018,20(8):753-760.
          [19]  FINDLING R L,MCNAMARA N K,PAVULURI M,        [29]  UMEHARA H,NAKAMURA M,NAGAI M,et al. Posi‐
              et al. Lithium for the maintenance treatment of bipolar Ⅰ  tional cloning and comprehensive mutation analysis of a
              disorder:adouble-blind,placebo-controlled discontinuation  Japanese family with lithium-responsive bipolar disorder
              study[J]. J Am Acad Child Adolesc Psychiatry,2019,58  identifies a novel DOCK5 mutation[J]. J Hum Genet,
              (2):287-296.e4.                                     2021,66(3):243-249.
          [20]  ALQAHTANI S,ALJUMA'AH N,AYDAN N B,et al.     [30]  AGHABOZORG AFJEH S S,SHAMS J,HAMEDNIA S,
              Estimation of lithium clearance in patients with bipolar  et al. Investigation of the impact of an ADCY2 polymor‐
              disorder[J]. Int Clin Psychopharmacol,2020,35(3):   phism as a predictive biomarker in bipolar disorder,sui‐
              157-162.                                            cide tendency and response to lithium carbonate therapy:
          [21]  PÉREZ-CASTELLÓ I,MANGAS-SANJUAN V,GONZÁLEZ-       the first report from Iran[J]. Pharmacogenomics,2020,21
              GARCÍA I,et al. Population pharmacokinetic model of  (14):1011-1020.
              lithium and drug compliance assessment[J].Eur Neuropsy‐       (收稿日期:2022-04-16 修回日期:2022-09-24)
              chopharmacol,2016,26(12):1868-1876.                                                 (编辑:孙 冰)








          中国药房    2022年第33卷第20期                                            China Pharmacy 2022 Vol. 33 No. 20  ·2555·
   128   129   130   131   132   133   134   135   136   137   138